Document Detail


Decreased total antioxidants status in the plasma of patients with pseudoexfoliation glaucoma.
MedLine Citation:
PMID:  22065931     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate total antioxidant status (TAS) in the plasma of pseudoexfoliation glaucoma (PEG) patients and to compare this level with a matching control group. Additionally, we aim to investigate the effect of the combined action of the lysyl oxidase-like 1 (LOXL1) mutation status with TAS level on the development of PEG.
METHODS: Plasma samples were obtained from 54 PEG patients and 54 controls of matching age, sex, and ethnicity. TAS in all samples was determined by spectrophotometric and enzyme-linked immunosorbent assay methods. The coding region of LOXL1, where it encompasses both single nucleotide polymorphisms (SNPs; rs1048661 and rs3825942), was sequenced.
RESULTS: The mean (±SD) total antioxidant (TAS) value was lower among patients: 0.87 (0.24), range 0.9-1.41 than controls: 1.07 (0.23), range 0.72-1.94, and this difference was statistically significant (p<0.0001: 95%CI: -0.295-0.114). Evaluating the impact of age, sex, and the mutation in addition to the mean TAS value in patients with PEG, a logistic regression analysis was conducted using diseased/not diseased as the outcome of interest (the dependent variable). Results show that, controlling for all other variables, mean TAS value (p<0.0001) and the mutation G/G in rs3825942 (p=0.041) are significant risk factors for PEG.
CONCLUSIONS: Our findings provide evidence that TAS decreases in the plasma of PEG patients, suggesting that TAS may have an important role in the pathogenesis of PEG. The combined effect of the "G" allele and the decreased TAS may contribute to the overall pathogenesis of PEG.
Authors:
Khaled K Abu-Amero; Altaf A Kondkar; Ahmed Mousa; Essam A Osman; Saleh A Al-Obeidan
Publication Detail:
Type:  Journal Article     Date:  2011-10-25
Journal Detail:
Title:  Molecular vision     Volume:  17     ISSN:  1090-0535     ISO Abbreviation:  Mol. Vis.     Publication Date:  2011  
Date Detail:
Created Date:  2011-11-08     Completed Date:  2012-02-29     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  9605351     Medline TA:  Mol Vis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2769-75     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. abuamero@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Alleles
Amino Acid Oxidoreductases / blood,  genetics*
Antioxidants / analysis*
Benzothiazoles / analysis
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Exfoliation Syndrome* / blood,  genetics
Female
Gene Frequency
Genetic Predisposition to Disease
Haplotypes
Humans
Male
Middle Aged
Polymorphism, Single Nucleotide
Regression Analysis
Saudi Arabia
Spectrophotometry
Sulfonic Acids / analysis
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Benzothiazoles; 0/Sulfonic Acids; 28752-68-3/2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid; EC 1.4.-/Amino Acid Oxidoreductases; EC 1.4.3.-/LOXL1 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel frame-shift mutation in FRMD7 causes X-linked idiopathic congenital nystagmus in a Chinese f...
Next Document:  A novel PIKFYVE mutation in fleck corneal dystrophy.